you need to read the preso to appreciate the significance of today's ann. To start with, the result was outstanding and it further increases the likelihood of success for other 3 phase 2 trials as they are more or less similar. Importantly, Neuren OWN the full commercial rights of all these indications and the potential size of the patient pool is 5 times bigger than Retts. FURTHER - there are hundreds of other autism related syndromes this drug can target. It's no longer a one trick pony but a full pipeline of indications!
Share Price, page-8405
-
- There are more pages in this discussion • 2,709 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |